Evidence map›Paper›PMID 36086680›Full record

SynthesisMedicine2022

Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.

Yuan Tian, Alan Huang, Mei Tian, Kaiyong Wang, Qi Dang, Caiqing Zhang, Hongmei Liu, Junyan Zhao, Xiaowei Yang, Chi Zhang and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Yuan TianRadiotherapy Department of Oncology, Shandong Second Provincial General Hospital, Jinan, Shandong 250023, P. R. China.ORCID 0000-0002-2296-1246
Alan HuangDepartment of Oncology, Jinan Central Hospital, the Hospital Affiliated with Shandong First Medical University, Jinan, Shandong 250013, P. R. China.
Mei TianRespiratory Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P. R. China.
Kaiyong WangDepartment of Respiratory and Critical Care Medicine, The People's Hospital of Yuncheng County, Heze, Shandong 274799, P. R. China.
Qi DangPhase I Clinical Trial Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250012, P. R. China.
Caiqing ZhangDepartment of Respiratory and Critical Care Medicine, Shandong Second Provincial General Hospital, Shandong University, Jinan, Shandong 250023, P. R. China.
Hongmei LiuRadiotherapy Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P. R. China.
Junyan ZhaoNursing Department, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250014, P. R. China.
Xiaowei YangDepartment of Hepatobiliary Intervention, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Chi ZhangCardiology Department, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250033, P. R. China.
Liang GuoRadiotherapy Department of Oncology, The Fourth People's Hospital of Jinan City, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Feng ChenDepartment of Thoracic surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Second Hospital of Shandong University · CNShandong Provincial QianFoShan Hospital · CNBeijing Tsinghua Chang Gung Hospital · CNJinan Central Hospital · CNShandong First Medical University · CNShandong Tumor Hospital · CNShandong University of Traditional Chinese Medicine · CNThe Fourth People's Hospital · CNZoucheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo elucidate the relationship between peripheral edema and programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors, the meta-analysis was performed.

methodFollowing the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses, all-grade and grade 3-5 of peripheral edema data extracted from clinical trials were taken into account for the final comprehensive assessments.

resultsTwenty-seven PD-1/PD-L1-related clinical trials with peripheral edema data were collected. Compared with chemotherapy (PD-1/PD-L1 vs chemotherapy), the risk of developing peripheral edema for all-grade was much lower (odds ratio [OR] = 0.36, 95% confidence interval [CI]: [0.23, 0.56], Z = 4.55 [P < .00001]). When PD-1/PD-L1 plus chemotherapy were compared with chemotherapy, no significant analysis results for all-grade was found (OR = 1.15, 95% CI:[0.93, 1.44], I2 = 25%, Z = 1.27 [P = .20]). Similar risk trends could also be found when the incidence risk of peripheral edema for grade 3-5 was evaluated. No obvious publication bias was identified throughout the total analysis process.

conclusionThe effect of PD-1/PD-L1 inhibitor on the risk of developing peripheral edema was weaker than that of chemotherapy, and the combination with chemotherapy slightly increased the incidence risk of developing peripheral edema without statistical significance.

Indexed as

B7-H1 AntigenNeoplasmsEdemaHumansImmune Checkpoint InhibitorsIncidenceProgrammed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Identifiers

PMID36086680
PMCPMC10980461
OpenAlexW4295029217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.